Yahoo
BSE - Delayed Quote INR

Syncom Formulations (India) Limited (SYNCOMF.BO)

21.03 +0.16 (+0.77%)
At close: 3:58:41 PM GMT+5:30
Chart Range Bar
Loading chart for SYNCOMF.BO
  • Previous Close 20.87
  • Open 20.89
  • Bid 20.89 x --
  • Ask 21.00 x --
  • Day's Range 20.68 - 21.20
  • 52 Week Range 10.21 - 27.53
  • Volume 290,000
  • Avg. Volume 1,330,876
  • Market Cap (intraday) 19.768B
  • Beta (5Y Monthly) 0.93
  • PE Ratio (TTM) 22.37
  • EPS (TTM) 0.94
  • Earnings Date (est.) --
  • Forward Dividend & Yield 0.10 (0.50%)
  • 1y Target Est --
  • Moby Rating Neutral

Syncom Formulations (India) Limited manufactures, markets, and sells pharmaceutical formulation products in India and internationally. It operates through Manufacturing and Dealing in Pharmaceutical Drug and Formulations, Trading of Commodities, and Renting of Properties segments. The company offers antibiotics/antiinfectives, anthelmintics, antimalarial, cardiac, derma, gastro, dry syrups and suspensions, creams, gel, ORS, jelly, gynae, inhalers, opthal, ortho, and pediatrics formulations in dosage forms. It also provides life care, evolve, and the right nutrition products under the Cratus brand. In addition, the company offers pharmaceutical formulation products in various dosage forms, such as tablets, capsules, ointments, injections, creams, liquids orals, and effervescent. Further, it provides liquid vials and ampoule injections, dry vial injections and inhalers; manufacturing and trading of nutraceuticals, dietary supplements, health supplements, functional foods, herbal and ayurvedic preparations, vitamins, minerals, proteins, antioxidants, natural extracts, organic and wellness products, and all related healthcare and nutrition-based goods and real estate business. Syncom Formulations (India) Limited was incorporated in 1988 and is based in Indore, India.

www.syncomformulations.com

902

Full Time Employees

March 31

Fiscal Year Ends

Healthcare

Sector

Recent News

View More

Performance Overview

Trailing total returns as of 11/8/2026, which may include dividends or other distributions. Benchmark is S&P BSE SENSEX (^BSESN) .

YTD Return

SYNCOMF.BO
48.10%
S&P BSE SENSEX (^BSESN)
4.95%

1-Year Return

SYNCOMF.BO
31.51%
S&P BSE SENSEX (^BSESN)
2.66%

3-Year Return

SYNCOMF.BO
131.22%
S&P BSE SENSEX (^BSESN)
24.66%

5-Year Return

SYNCOMF.BO
97.09%
S&P BSE SENSEX (^BSESN)
33.78%

Statistics

View More

Valuation Measures

Annual
  • Market Cap

  • Enterprise Value

  • Trailing P/E

  • Forward P/E

  • PEG Ratio (current)

  • Price/Sales (ttm)

  • Price/Book (mrq)

  • Enterprise Value/Revenue

  • Enterprise Value/EBITDA

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    17.18%

  • Return on Assets (ttm)

    --

  • Return on Equity (ttm)

    --

  • Revenue (ttm)

    4.98B

  • Net Income Avi to Common (ttm)

    855.3M

  • Diluted EPS (ttm)

    0.94

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    1.13B

  • Total Debt/Equity (mrq)

    0.35%

  • Levered Free Cash Flow (ttm)

    --

Company Insights

Research Reports

View More

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: